Inova Schar Cancer
Inova Schar Cancer
Fairfax, Virginia, United States8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1 Study of PF-08046033 in Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, cutaneous melanoma, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-10-06 | NCT07519655 | |
| VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), astrocytoma, IDH-mutant, grade 4, epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-09-21 | NCT07831369 | |
| Early Screening and Treatment of Heart Complication in Sickle Cell Disease | Arrhythmias, Cardiac, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anemia, cardiomyopathy, cardiovascular disorder, familial hemolytic anemia, heart disorder, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, iron metabolism disease, iron poisoning, metabolic disease, sickle cell disease | Recruiting | Phase 2 | 2026-09-09 | NCT07023666 | |
| A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-09-01 | NCT06992258 | |
| Pre-Operative Window of ET to Inform RT Decisions (POWER II) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-06-30 | NCT06507618 | |
| Study of XB010 in Subjects With Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, squamous cell carcinoma, squamous cell neoplasm, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-06-22 | NCT06545331 | |
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | DNA Virus Infections, Infections, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, skin disorder, skin neoplasm, viral infectious disease | Recruiting | Phase 2 / Phase 3 | 2026-04-17 | NCT06947928 | |
| A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity | EGFR Inhibitor-associated Rash | Recruiting | Phase 1 / Phase 2 | 2026-02-11 | NCT06830863 |